Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019
About Acquired Orphan Blood Diseases Therapeutics
Acquired orphan blood diseases are rare disorders and are characterized by the body's inability to produce a sufficient amount of RBCs. This is basically because of the improper functioning of bone marrow to produce RBCs in the blood. This leads to a decrease in platelet counts, which can eventually lead to anemia and thrombosis. The acquired orphan blood diseases are developed in the blood after the post fetal life; they are not caused because of genetic reasons. The major orphan blood diseases that contribute to acquired orphan blood diseases are the following: ITP, MDS, MF PNH, and PV.
TechNavio's analysts forecast the Global Acquired Orphan Blood Diseases Therapeutics market to grow at a CAGR of 12.29 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Acquired Orphan Blood Diseases Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sale of marketed drugs used in the treatment of PNH, ITP, PV, MF, and MDS.
TechNavio's report, the Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Acquired Orphan Blood Diseases Therapeutics market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
TechNavio Announces the Publication of its Research Report – Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019
TechNavio recognizes the following companies as the key players in the Global Acquired Orphan Blood Diseases Therapeutics Market: Alexion Pharmaceuticals, Amgen plc, Celgene Corp., F. Hoffmann-La Roche Ltd., GlaxoSmithKline and Incyte Corp.
Other Prominent Vendors in the market are: CTI BioPharma (Cell Therapeutics), Cyclacel Pharmaceuticals, Eli Lilly, Gilead Sciences, MabVax Therapeutics, Novartis, Onconova Therapeutics, Sanofi, Shire Pharmaceuticals and S* Bio.
Commenting on the report, an analyst from TechNavio’s team said: “Entry into untapped markets is one of the major trends upcoming in the market. Currently, the market in many geographical locations remains untapped and provides immense opportunities for vendors to invest in the same. Companies that are pioneers in the development of drugs for acquired orphan blood diseases target physicians who prescribe patients these drugs instead of surgeries and chemotherapy. This has helped manufacturers to increase their product price.”
According to the report, patients diagnosed with acquired orphan blood diseases mostly rely on generics for the treatment. Side effects of these drugs are high and the treatment regimen requires high level of commitment from patients such as regular hospital visits and checkups.
Further, the report states that most pharmaceutical and biotech companies invest extensively in the development of novel drugs to treat rare diseases. However, when marketing and distribution of drugs to potential consumers is taken into consideration, companies are hesitant to invest for the same. Low prevalence of orphan diseases makes it difficult for companies to locate the target population.
Alexion Pharmaceuticals, Amgen, Celgene, F. Hoffmann- La Roche, GlaxoSmithKline, Incyte , Cyclacel Pharmaceuticals, CTI Biopharma (Cell Therapeutics), Eli Lilly, GileadSciences, Onconova Therapeutics, MebVax Therapeutics, Novartis, Sanofi, Shire Pharmaceuticals, S* Bio Pte